Pozen pockets $10M milestone; Eurand shares rise on FDA approval;

> Pozen earned a $10 million milestone payment and a bump in its stock price on this morning's announcement that the FDA has accepted its marketing application for the pain drug Vimovo. The therapy combines AZ's Nexium and naproxen, a generic anti-inflammatory. Release | Story

> Shares of Eurand shot up 32 percent on Friday after the European developer announced that the FDA had approved its pancreatic enzyme drug Zenpep. A launch is planned in the next quarter. Release | Report

> Lonza has struck a deal to sell its cell culture biologic manufacturing facility to a subsidiary of Roche for $360 million. Report

> The FDA has provided Delcath Systems with an orphan drug indication for its experimental cancer treatment doxorubicin. Its shares soared 48 percent on the news. Story

> The drug discovery group Mondobiotech says that it will issue new shares every two months, raising $4.7 million to $9.4 million in each round. Mondobiotech listed on the Swiss exchange last week, the first healthcare company to do so since 2007. Report

> The FDA has approved Valcyte--valganciclovir hydrochloride--for the prevention of cytomegalovirus (CMV) disease in kidney and heart transplant patients 4 months to 16 years of age at high risk of developing CMV disease. Release

> PsychoGenics and AstraZeneca have inked a deal to collaborate on new therapies for central nervous system disorders. Release

Pharma News

> Curious about the woman who's charged with cleanup at Genzyme? Skip on over to the Boston Globe, where Sandra E. Poole gets the profile treatment. Poole, who took over in July as Genzyme's senior vice president and site leader at the embattled Allston Landing facility, is pushing hard to get the plant--and Genzyme's reputation--back on line. Report

> Sanofi-Aventis is exchanging the "For Sale" sign on its Kansas City plant for another that says, "Closed." After scouting for a buyer for more than a year, the drugmaker is shutting down the facility, which employs 370 people. Workers were told during a site meeting late last week. Report

> The Capitol's chief bean-counters, the Congressional Budget Office, have ruled on new House legislation governing Medicare prescription coverage. And in some unwelcome news for the over-65s, drug premiums are set to rise by about 5 percent in 2011 and the hike would grow to 20 percent by 2019. Nevertheless, the advocacy group AARP deemed the CBO report as evidence that "healthcare reform will lower drug spending." Report

IT News

> An association has formed for digital pathologists. Goals of the nonprofit, called the Digital Pathology Association, include defining best practices and influencing standards and interfaces. Education and a conference are also on the list. Report

> Researchers can use the Applied Semantic Knowledgebase to build a collection of models built from their research, then apply the models to visualizing and validating data-driven hypotheses. The models can also be used for knowledge-based screening. Report

> Evaluation of newly designed synthetic routes and identification of drugs in development are features of an update to the organic synthesis knowledge area within the Prous Science Integrity portal. Article

And Finally... New York collaborators at Columbia and Rockefeller Universities have identified cells in the stomach that time the release of a hormone that makes animals anticipate food and eat even when they are not hungry. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.